TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7492131

Group type: EXPERIMENTAL
Intervention: Q‐switched ruby laser (wavelength, 694 nm; beam diameter, 5.0 mm) at a fluence of 6.0 J/cm2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Frequency‐doubled Q‐switched neodymium:YAG laser (wavelength, 532 nm; beam diameter, 2.0 mm) at a fluence of 6.0 J/cm2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both lasers
Number of subjects: 9
Study: 2401126

Group type: EXPERIMENTAL
Intervention: 4.2 mg/kg/day caffeine (low dose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 12 mg/kg/day caffeine (high dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 363334

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and spironolactone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Spironolactone (up to 100 mg/day)
Number of subjects: 49
Study: 31502382

Group type: EXPERIMENTAL
Intervention: Pylera® (2 capsules) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gastrus® (2 x 10^8 CFU L reuteri DSM 17 938 plus 2 x 10^8 CFU L reuteri ATCC PTA 6475) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pylera®
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gastrus®
Number of subjects: 99
Study: 28145948

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty after ACL reconstruction
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (primary osteoarthritis, no history of ligament reconstruction)
Number of subjects: 122
Study: 26371270

Group type: EXPERIMENTAL
Intervention: CEASE intervention arm
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1980
Study: 23352174

Group type: EXPERIMENTAL
Intervention: Immunoenriched formula (IEF group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous placebo diet (Con group)
Number of subjects: 108
Study: 21436393

Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) group
Number of subjects: 16

Group type: COMPARATOR
Intervention: No RAS group (internally paced stepping)
Number of subjects: 16
Study: 20032538

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha2a treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 14
Study: 17234020

Group type: EXPERIMENTAL
Intervention: Education and activation program (EAP) in addition to usual care (UC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 0
Study: 14710212

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² and cisplatin 80 mg/m² on day 1 (DC)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² on day 8 and irinotecan 60 mg/m² on day 1 and 8 (DI)
Number of subjects: 108
Study: 11689751

Group type: EXPERIMENTAL
Intervention: Anthropometric (ANTHRO) estimates of total body and leg fat-free mass (FFM)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometric (DEXA) estimates of total body and leg fat-free mass (FFM)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Peak VO2 corrected for FFMANTHRO
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Peak VO2 corrected for FFMDEXA
Number of subjects: 77
Study: 9424908

Group type: EXPERIMENTAL
Intervention: Thrombin-adrenaline solution (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fibrin sealant-Beriplast (Group II)
Number of subjects: 30
Study: 7524291

Group type: EXPERIMENTAL
Intervention: TZP-4238
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMA (Chlormadinone Acetate)
Number of subjects: 0
Study: 3284530

Group type: EXPERIMENTAL
Intervention: Thymopentin (Timunox) 1 ml (50 mg) plus lidocaine 1 ml (2%), once a week for 5 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Methylprednisolone depot 1 ml (40 mg) plus lidocaine 1 ml (2%)
Number of subjects: 122
Study: 31791087

Group type: EXPERIMENTAL
Intervention: Downhill exercise (‐15%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Uphill exercise (+15%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Level exercise (+1%)
Number of subjects: 9
Study: 29246818

Group type: EXPERIMENTAL
Intervention: Self-administration of DMPA
Number of subjects: 401

Group type: COMPARATOR
Intervention: Clinic administration of DMPA
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 401
Study: 28355979

Group type: EXPERIMENTAL
Intervention: Physical therapy care
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SBST administered at different time points
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SBST at baseline
Number of subjects: 148
Study: 24434827

Group type: EXPERIMENTAL
Intervention: Daily feedback messages (DFB group; n = 70)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard behavioral intervention for weight loss (both groups)
Number of subjects: 210
Study: 22509750

Group type: EXPERIMENTAL
Intervention: 0.5% MF gel
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 1% MF gel
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 1.5% MF gel
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 118
Study: 21365405

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program (quarterly follow-up by a hospital pharmacist for 9 months)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No pharmaceutical care (control group)
Number of subjects: 197
Study: 18440341

Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 6325
Study: 16390859

Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNB) with ropivacaine 0.25%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNB) with lidocaine 1%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurements (no intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNB)
Number of subjects: 10
Study: 14576536

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg succinylcholine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.0 mg/kg succinylcholine (saline control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.56 mg/kg succinylcholine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.24 mg/kg succinylcholine
Number of subjects: 200
Study: 10630716

Group type: EXPERIMENTAL
Intervention: Brief physician advice
Number of subjects: 774

Group type: COMPARATOR
Intervention: Control group (no brief physician advice)
Number of subjects: 774
Study: 8960574

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 22516
Study: 1413942

Group type: EXPERIMENTAL
Intervention: Beta-sympathomimetics + transcutaneous dorsal nerve stimulation (TNS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Beta-sympathomimetics alone
Number of subjects: 114
Study: 3937549

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg, oral, twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29800408

Group type: EXPERIMENTAL
Intervention: Choices (bilingual multi‐component intervention)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (general clinical trial information)
Number of subjects: 77
Study: 27887597

Group type: EXPERIMENTAL
Intervention: Ability Program (tablet-delivered cognitive activities 5 days/week, physical activities 7 days/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) (paper and pencil cognitive activities 5 days/week, clinician's prescribed physical exercise daily)
Number of subjects: 30
Study: 25008457

Group type: EXPERIMENTAL
Intervention: Abstinence incentive intervention
Number of subjects: 147
Study: 21933467

Group type: EXPERIMENTAL
Intervention: Training of family planning service providers in information exchange and training of their supervisors in facilitative supervision
Number of subjects: 0
Study: 20420992

Group type: EXPERIMENTAL
Intervention: Patient-centered advance care planning (PC-ACP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 18184326

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen screening
Number of subjects: 87
Study: 15918201

Group type: COMPARATOR
Intervention: Water drinking test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nutritional beverage (Nutren) drinking test
Number of subjects: 40
Study: 14971618

Group type: EXPERIMENTAL
Intervention: Gated blood pool SPECT (GBPS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Planar radionuclide angiography (PRNA)
Number of subjects: 43
Study: 11211124

Group type: EXPERIMENTAL
Intervention: Running at 35 degrees C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8-km run at 35 degrees C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heat storage at 35 degrees C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heat storage at 25 degrees C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Potential evaporation at 35 degrees C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Decreased rate of heat production during 8-km run
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mean running speed during 8-km run
Number of subjects: 16
Study: 9388311

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine treatment (dextran, nicotinic acid, aspirin, dipyridamole, radix salviae miltiorrhizae composita)
Number of subjects: 64
Study: 1417538

Group type: EXPERIMENTAL
Intervention: Optisol
Number of subjects: 62

Group type: COMPARATOR
Intervention: DexSol
Number of subjects: 62
Study: 6378807

Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Free questionnaire
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Conventional evaluation by physician
Number of subjects: 227
Study: 31099300

Group type: COMPARATOR
Intervention: Blood serum markers (BDNF, IGF‐1, VEGF, TGF‐β 1, MCP‐1, IL‐18)
Number of subjects: 160
Study: 29474410

Group type: EXPERIMENTAL
Intervention: PHQ-9 screening tool for depression
Number of subjects: 836
Study: 27077879

Group type: EXPERIMENTAL
Intervention: 25 mL/day of PC-enriched OO containing 500 mg PC/kg (FVOO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 25 mL/day of OO containing 80 mg PC/kg (VOO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 25 mL/day of OO containing a mixture of 500 mg PC/kg from OO and thyme (FVOOT)
Number of subjects: 10
Study: 25263837

Group type: COMPARATOR
Intervention: Online support (resources plus website and e-feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help paper-based resources (gender-tailored weight loss resources including DVD, handbooks, pedometer, tape measure)
Number of subjects: 0
Study: 22422361

Group type: EXPERIMENTAL
Intervention: Dolutegravir 250 mg suspension
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg tablet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo suspension
Number of subjects: 42
Study: 21252455

Group type: EXPERIMENTAL
Intervention: Short-course acyclovir therapy (800 mg five times a day for four days)
Number of subjects: 152
Study: 17279850

Group type: EXPERIMENTAL
Intervention: Participants rated fictional partners in happier relationships
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' judgments of their own current partners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metaperceptions of bias in couples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive bias for traits relevant to mate evaluation
Number of subjects: 0
Study: 11246613

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b, 3 MU three times a week for 6 months (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (group 1)
Number of subjects: 80
Study: 9307221

Group type: EXPERIMENTAL
Intervention: poly(L-lactide) osteosynthesis plug
Number of subjects: 15
Study: 8354200

Group type: EXPERIMENTAL
Intervention: 5000 IU of vitamin A
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 100 IU of vitamin E
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Combination of vitamins A and E (5000 IU + 100 IU)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 16 mg of beta-carotene
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 2872913

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction and contact lens usage (Group A)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Extracapsular extraction and implantation of an iridocapsular lens (Group C)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Intracapsular extraction and implantation of an iris supported lens (Federov I) (Group B)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Both implant groups (Groups B and C)
Number of subjects: 333
Study: 30789384

Group type: EXPERIMENTAL
Intervention: Mannitol 0.7 g/kg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Mannitol 1.0 g/kg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Mannitol 1.4 g/kg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 27425388

Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo prism training
Number of subjects: 43
Study: 27754419

Group type: EXPERIMENTAL
Intervention: 6mg/kg of caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24622117

Group type: EXPERIMENTAL
Intervention: Hypothyroid patients
Number of subjects: 4987

Group type: COMPARATOR
Intervention: Euthyroid patients
Number of subjects: 4987

Group type: EXPERIMENTAL
Intervention: After adjustment for other predictors
Number of subjects: 4987
Study: 22914404

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 20026804

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m²/d
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 113

Group type: COMPARATOR
Intervention: CCR
Number of subjects: 113
Study: 18449445

Group type: EXPERIMENTAL
Intervention: Arginine-enhanced formula
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard polymeric formula
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Arginine, RNA and omega-3 fatty acids enhanced formula
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enhanced diet groups
Number of subjects: 44
Study: 16001233

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1.0 mg/day
Number of subjects: 390
Study: 12556267

Group type: EXPERIMENTAL
Intervention: 2-implant overdenture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional complete dentures
Number of subjects: 30
Study: 10657821

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1358
Study: 8665355

Group type: EXPERIMENTAL
Intervention: Portocaval or splenorenal anastomosis (group I)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Esophageal transection or variceal sclerosis (group II)
Number of subjects: 232
Study: 1500660

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antacids (magnesium hydroxide and aluminum hydroxide)
Number of subjects: 0
Study: 31815528

Group type: EXPERIMENTAL
Intervention: HASMEP-T (HIV/AIDS self-management education program)
Number of subjects: 40
Study: 27927683

Group type: EXPERIMENTAL
Intervention: Potassium Nitrate (KNO3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Potassium Chloride (Control)
Number of subjects: 12
Study: 25765698

Group type: EXPERIMENTAL
Intervention: Clinic plus community support (screening for serum cryptococcal antigen, antifungal therapy for positive cases, weekly home visits for 4 weeks)
Number of subjects: 1999

Group type: COMPARATOR
Intervention: Standard care (clinic-based care alone)
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: Clinic plus community support
Number of subjects: 1999

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1999
Study: 23340440

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) gel, 0.5mL injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (control)
Number of subjects: 60
Study: 21795436

Group type: EXPERIMENTAL
Intervention: Fragmented sleep
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonfragmented sleep
Number of subjects: 15
Study: 19386741

Group type: EXPERIMENTAL
Intervention: Oligofructose supplementation (21 g/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 48
Study: 18596121

Group type: EXPERIMENTAL
Intervention: multitarget therapy (mycophenolate mofetil, tacrolimus, and steroids)
Number of subjects: 40

Group type: COMPARATOR
Intervention: intravenous cyclophosphamide (IVCY)
Number of subjects: 40
Study: 16000607

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin-based)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study: 12638280

Group type: EXPERIMENTAL
Intervention: Patients with IBS seeking medical assistance
Number of subjects: 338

Group type: COMPARATOR
Intervention: General population with IBS symptoms
Number of subjects: 338

Group type: COMPARATOR
Intervention: General population
Number of subjects: 338

Group type: COMPARATOR
Intervention: IBS subjects
Number of subjects: 338
Study: 10624645

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study: 7555938

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 15-French tube
Number of subjects: 22

Group type: COMPARATOR
Intervention: 20-French tube
Number of subjects: 22
Study: 1951163

Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (FOC) supplemented with 15 mg alpha-tocopherol/d for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (FOC) plus an additional 200 mg alpha-tocopherol/d for 8 weeks (FOC+E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oil (PO) for 10 weeks
Number of subjects: 0
Study: 7033573

Group type: EXPERIMENTAL
Intervention: Allopurinol during chemotherapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (no allopurinol) during chemotherapy
Number of subjects: 143
Study: 29343089

Group type: EXPERIMENTAL
Intervention: Reciprocal peer support arm
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nurse care management arm
Number of subjects: 102
Study: 27910203

Group type: EXPERIMENTAL
Intervention: Designing and conducting DNA extraction with household materials
Number of subjects: 47
Study: 26186592

Group type: EXPERIMENTAL
Intervention: Rikkunshito 7.5 g/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rikkunshito 5.0 g/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rikkunshito 2.5 g/day
Number of subjects: 21
Study: 23855301

Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived mesenchymal stem cell (UC-MSC) transfusion, 0.5×10^6 cells/kg body weight, infused three times at 4-week intervals.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived mesenchymal stem cell (UC-MSC) transfusion
Number of subjects: 7
Study: 20662674

Group type: EXPERIMENTAL
Intervention: Self-aligning attachment system
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional ball attachment system
Number of subjects: 25
Study: 19552918

Group type: EXPERIMENTAL
Intervention: Developmentally appropriate face identity aftereffect (FIAE) task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptation to facial identity
Number of subjects: 0
Study: 17467914

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 19
Study: 15179174

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study: 11570735

Group type: EXPERIMENTAL
Intervention: Augmented feedback
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sensory feedback
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control I
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control II
Number of subjects: 63
Study: 9748036

Group type: EXPERIMENTAL
Intervention: Vestibular exercises
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no vestibular exercises)
Number of subjects: 39
Study: 7872714

Group type: EXPERIMENTAL
Intervention: p53-positive leukemic cells
Number of subjects: 91

Group type: COMPARATOR
Intervention: p53-negative leukemic cells
Number of subjects: 91
Study: 3337013

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (65 to 75% VO2max)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (less than 45% VO2max)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both groups (high and low intensity)
Number of subjects: 45
Study: 29855452

Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chair rising time
Number of subjects: 0
Study: 27105601

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlordiazepoxide (75 mg)
Number of subjects: 60
Study: 25656258

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (TA) with standard polyurethane dressing (SPU)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing (BPU) with SPU
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sutureless securement device (SSD) with SPU
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard polyurethane dressing (SPU)
Number of subjects: 85